| Name | Title | Contact Details |
|---|
Banyan Biomarkers Inc is a Alachua, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MB Research Laboratories is a Spinnerstown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.